Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron vs Dulaglutide in Pediatric Type 2 Diabetes
NCT07668336Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Primary completion
- Mar 2030
- Countries
- 11
01
Overview
A Phase 3 trial of orforglipron in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jul 2026; status: recruiting.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07668336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07668336.